Verastem (VSTM) Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings or view top-rated stocks.

6 brokers have issued 1 year price objectives for Verastem's shares. Their VSTM share price forecasts range from $24.00 to $72.00. On average, they expect the company's share price to reach $43.20 in the next twelve months. This suggests a possible upside of 292.7% from the stock's current price.
View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts.

Verastem's stock was trading at $4.83 at the beginning of the year. Since then, VSTM stock has increased by 127.7% and is now trading at $11.00.
View the best growth stocks for 2023 here.

Verastem saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 981,400 shares, a decrease of 21.5% from the April 30th total of 1,250,000 shares. Based on an average trading volume of 649,600 shares, the days-to-cover ratio is presently 1.5 days.
View Verastem's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our VSTM earnings forecast.

Verastem, Inc. (NASDAQ:VSTM) issued its quarterly earnings data on Tuesday, March, 14th. The biopharmaceutical company reported ($0.96) EPS for the quarter.

Verastem shares reverse split on the morning of Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Verastem's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (12.71%), Acadian Asset Management LLC (1.24%), Geode Capital Management LLC (0.94%), Two Sigma Advisers LP (0.30%), Dimensional Fund Advisors LP (0.23%) and Two Sigma Investments LP (0.09%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins, Ra Capital Management, LP, Robert E Gagnon and Timothy J Barberich.
View institutional ownership trends.

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VSTM stock can currently be purchased for approximately $11.00.

Verastem (NASDAQ:VSTM) has a market capitalization of $184.03 million and generates $2.60 million in revenue each year. The biopharmaceutical company earns $-73,810,000.00 in net income (profit) each year or ($4.4418) on an earnings per share basis.

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The official website for the company is www.verastem.com. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at bsullivan@verastem.com.